Galecto Inc. is a biotechnology company focused on developing innovative therapies for fibrotic diseases and cancer. By leveraging its expertise in glycoscience, the company aims to create small molecule drugs that target specific pathological processes associated with these conditions. Galecto's research emphasizes the importance of the extracellular matrix in disease progression, and its pipeline includes candidates that seek to address critical unmet medical needs. The company's commitment to advancing scientific knowledge is coupled with a goal of improving patient outcomes through novel treatment options. Read More
Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Galecto shares are trading lower by 27% during Monday's session. The company issued 62,594 common and 160,562 preferred convertible shares to Bridge Medicine for BRM-1420 acquisition rights.
